Home » Meningococcal B vaccination for infants and younger kids is now obligatory for all…

Meningococcal B vaccination for infants and younger kids is now obligatory for all…

by admin
Meningococcal B vaccination for infants and younger kids is now obligatory for all…

04.06.2024 – 13:33

GlaxoSmithKline GmbH & Co. KG

Munich (stones)

In order to make sure the most effective safety in opposition to meningococcal ailments, the Standing Vaccination Commission (STIKO) prolonged its suggestions for vaccination of kids and younger kids in January 2024 and now recommends, along with the usual meningococcal C vaccination, the usual meningococcal B vaccination. Both vaccines needs to be carried out as quickly as potential. However, the prolonged STIKO suggestion consists of the meningococcal B vaccine as much as the fifth day of beginning. [1] This new routine vaccination was included within the immunization information (SI-R) by the Federal Joint Committee (G-BA) in March/April 2024. [2] After evaluation by the State Department of Health and publication within the Federal Gazette [3] the choice of the G-BA has come into drive. [4]

This signifies that meningococcal B vaccination for infants and younger kids is now a part of the obligatory companies offered by official medical insurance firms. It is now obligatory for all medical insurance firms. Once vaccination is included in regional vaccination agreements between official medical insurance organizations (KVen) and medical insurance firms, regulation on the necessity for contact hours (SSB) and insurance coverage card billing is feasible.

Implementation of regional vaccination agreements makes administration and billing simpler

Vaccination is included within the regional vaccination agreements for KVs at completely different speeds, with a deadline of three months. [5] Until then – even though the insured particular person has the best to obtain advantages – the reimbursement course of remains to be energetic: As earlier than, docs give vaccinations with a non-public letter, the bill goes to the medical insurance firm and the quantity is obliged to be reimbursed by the insurance coverage firm. As quickly as KV negotiations with medical insurance firms are accomplished and the use, billing and reimbursement of vaccinations are regulated contractually, regulation by SSB and insurance coverage card billing is feasible. This is anticipated to be the case all through the nation by August 2024.

See also  A new image of the super black hole and its magnetic field

Meningococcal infections might be life-threatening

Although meningococcal infections are very uncommon, they will result in life-threatening meningitis or sepsis inside hours with severe penalties comparable to scarring and amputation. [6] Babies and younger kids are at excessive danger of sickness as a result of their immune methods usually are not but totally developed. [7] Despite intensive remedy, problems and long-term results comparable to listening to loss, blindness, scarring or lack of limbs resulting from amputation could happen in 20% of sufferers. [8] Meningococcal group B is at present accountable for almost all of meningococcal infections in Germany at 62%, adopted by Y, W and C. [9] For full safety, the meningococcal ACWY vaccination can also be potential, which is advisable particularly when you journey, however usually are not but a part of the common vaccination program.

The suggestions of STIKO embrace the ideas of holding

Most meningococcal infections happen in kids underneath 5 years of age, and the danger is highest within the first 12 months of life. STIKO subsequently recommends that two routine vaccinations in opposition to meningococcal illness be administered as quickly as potential and that vaccines that haven’t been administered needs to be administered as quickly as potential. Meningococcal B vaccination is advisable on the fifth birthday if there was no earlier vaccination.

Parents ought to now speak to their pediatrician concerning the completely different meningococcal vaccines and ask for suggestions.

More data at: www.meningitis-bewegt.de.

NP-DE-MNU-PRSR-240012; 05/2

About GSK

GSK is a world biopharmaceutical firm that brings science, know-how and expertise collectively to enhance illness. More data at: www.de.gsk.com.

See also  Vaccine to children, prof. Cavaleri (EMA): "More than 90% safe and effective. Fewer events ... - La7 News

You can go to or subscribe to our newsroom: www.presseportal.de/nr/39763

[1] RKI: “Epidemiological Bulletin 03/2024”. Available underneath: https://bit.ly/3O6N2PX. April 2024.

[2] G-BA modification to the vaccination information: Application of the “Meningococcal B vaccination suggestion” from 7 March 2024 together with modifications from 4 April 2024. Available: https://www.g-ba.de/beschluesse/6500/.

[3] Federal Ministry of Justice. Federal Gazette. Announcement of the choice of the Federal Joint Committee relating to the change within the vaccination order: the implementation of the “STIKO suggestion for meningococcal B vaccination” from: January 18, 2024.

[4] Federal Ministry of Health – Announcement of the choice of the Federal Joint Committee on the change within the vaccination tips: Implementation of the “Meningococcal B vaccination suggestion”: Official publications – Federal Gazette. May 2024.

[5] SGB ​​V (Book Five – Social Security Code). § 132e.

[6] BZgA: “Meningococcal pathogen profile”. Available underneath: https://bit.ly/34WO5Zw. April 2024.

[7] German Green Cross: “Frequently requested questions and solutions about meningococcal ailments”. Available underneath: https://bit.ly/2X7aroA. April 2024.

[8] German Green Cross: “Frequently requested questions and solutions about meningococcal ailments”. Available underneath: https://bit.ly/2O8tlaw. April 2024.

[9] RKI: SurvStat@RKI 2.0, https://survstat.rki.de. Status: Epidemiological Yearbook 2022. Case numbers in accordance with reference definition; Reporting obligation in accordance with the IfSG; Meningococcal ailments with details about serogroup. April 2024.

Press the contact:

Andrea Guggenberger
Disease Awareness Communications Manager
Phone: +49 173 8176831
Email: [email protected]

Jana König-Petermaier
Communications Team Leading Communications, Government Affairs and Market Outreach
Phone: +49 174210 37 27
Email: [email protected]

Fabienne Lessenich
Agency contact
Phone: +49 221 9257 3840
Email: [email protected]

GlaxoSmithKline GmbH & Co. KG, Prinzregentenplatz 9, 81675 Munich
KG headquarters in Munich
Munich District Court HRA 78754
Common companion:
Allen Pharmazeutika Gesellschaft mbH, headquarters in Vienna
Vienna Commercial Court FN 93449 a
Managers: René Jensen

See also  Alzheimer's disease, new genetic variants associated with the disease identified

Original content material from: GlaxoSmithKline GmbH & Co. KG, broadcast by information aktuell

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy